Key Takeaway: The article discusses the presentation of additional Phase 2a study data for nimacimab at the ObesityWeek Medical Conference. This presentation highlights the ongoing research efforts surrounding the treatment of obesity. The event serves as a platform for sharing significant advancements in the field.
Price reaction · baseline $1.52 (2025-11-06 close) · hit pre-market · 2 other SKYE headline(s) in the window, move may be shared
day 0 close
+0.7%
Market Sentiment Analysis
POSITIVE FACTORS
Presentation of additional Phase 2a study data.
Focus on nimacimab, indicating ongoing research.
Engagement at ObesityWeek, a significant medical conference.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+84%
120-day peak, hindsight
Typical move
24.3%
average across 4 past catalysts
Cash runway
~4 mo
High dilution risk
Lead asset
Nimacimab
Phase 2 · Obesity
Full Press Release Details
All Primers Perspectives Progress Press ObesityWeek Presentation: Additional P2a Study Data Date published: November 7, 2025 1:23 pm PST Share Related Documents: ObesityWeek Medical Conference Presentation of P2a Data for Nimacimab
Frequently Asked Questions
What was presented at ObesityWeek?
Additional Phase 2a study data for nimacimab was presented.
When was the ObesityWeek presentation?
The presentation took place on November 7, 2025.
What is nimacimab used for?
Nimacimab is being researched for the treatment of obesity.
What type of conference is ObesityWeek?
ObesityWeek is a significant medical conference focused on obesity research.